{"a":[{"_":"GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal","$":{"href":"/pharma/gsk-secures-first-ever-lung-cancer-fda-approval-jideytro-nuvalent-deal","hreflang":"en"}}]}
RegulatoryapprovedJideytroPositive
AI Analysis
Summary
GSK received FDA approval for Jideytro, marking the company's first-ever lung cancer drug approval, following its $10.6 billion acquisition of Nuvalent.
Outcome Details
FDA approval for Jideytro as first lung cancer drug in GSK's commercial history
Importance:9/10
Sentiment:
0.95
FDA approvaloncologylung canceracquisitionmilestone
Read the original article
Published by FiercePharma on July 22, 2026 2:54 PM